Top Markets
Coin of the day
WayPoint Biomedical Holdings, Inc. WayPoint Biomedical Holdings, Inc.

WayPoint Biomedical Holdings, Inc.

WYPH
Rank in Stocks #41072
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary,... WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests for cocaine and marijuana detection. The company also develops and commercializes test kits for detection against possible explosive devices, biowarfare/bioterrorism agents, and the detection of weapons of mass destruction. In addition, it provides Frontline Explosive Test Kit for the detection of explosive residues. The company offers its products to the over-the-counter diagnostic self-testing, the diagnostic point of care, and the homeland security and defense markets. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California.
Share Price
$0.0005
Last synced: 2026-08-12
Market Cap
$16.62K
Change (1 day)
-64.29%
Change (1 year)
400.00%
Country
US
Trade WayPoint Biomedical Holdings, Inc. (WYPH)

Category

Earnings for WayPoint Biomedical Holdings, Inc. (WYPH)
Earnings in 2026 TTM: 0
According to WayPoint Biomedical Holdings, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for WayPoint Biomedical Holdings, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$2.51B -
US
- -
CA
$1.91B -
US
$1.33B -
AU
$608.48M -
US